Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00902265
Other study ID # FE992026 CS33
Secondary ID
Status Completed
Phase N/A
First received May 14, 2009
Last updated April 15, 2011
Start date February 2009
Est. completion date March 2010

Study information

Verified date April 2011
Source Ferring Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority Germany: Federal Institute for Drugs and Medical Devices
Study type Observational

Clinical Trial Summary

Documentation of the efficacy and safety of desmopressin (Nocturin®) 0.1 mg tablet. Observation of patients with benign prostate syndrome, in whom nocturia associated with nocturnal polyuria is treated with desmopressin (Nocturin®) 0.1 mg tablet focusing on number of nocturnal voids, ratio of night/24-h urine volume (%), duration of first undisturbed sleep period and quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 138
Est. completion date March 2010
Est. primary completion date March 2010
Accepts healthy volunteers No
Gender Male
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Therapeutic need according to Summary of Product Characteristics

- Written informed consent

Exclusion Criteria:

- Contraindications according to Summary of Product Characteristics

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


Intervention

Drug:
desmopressin
desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks

Locations

Country Name City State
Germany Investigational Site - Pauwelsstraße 30 Aachen
Germany Investigational Site - Sanatoriumstraße 10 Aachen
Germany Investigational Site Arnsberg
Germany Investigational Site Bad Bergzabern
Germany Investigational Site Bad Schönborn
Germany Investigational Site Baierbrunn
Germany Investigational Site Bergisch Gladbach
Germany Investigational Site - Breite Straße 37 Berlin
Germany Investigational Site - Britzer Damm 63 Berlin
Germany Investigational Site - Florastraße 44 Berlin
Germany Investigational Site - Fritz-Reuter-Straße 6-8 Berlin
Germany Investigational Site - Heerstraße 435 Berlin
Germany Investigational Site - Kaiserdamm 12 Berlin
Germany Investigational Site - Kurfürstendamm 33 Berlin
Germany Investigational Site - Marburger Straße 12/13 Berlin
Germany Investigational Site - Mehrower Allee 22 Berlin
Germany Investigational Site - Rüdesheimer Straße 43 Berlin
Germany Investigational Site - Schnellerstraße 123 Berlin
Germany Investigational Site - Tempelhofer Damm 214 Berlin
Germany Investigational Site - Turmstraße 82 Berlin
Germany Investigational Site Biberach
Germany Investigational Site Bochum
Germany Investigational Site Bonn
Germany Investigational Site - Friedrich-Wilhelm-Str. 43/44 Braunschweig
Germany Investigational Site - Güldenstraße 19-20 Braunschweig
Germany Investigational Site - Humboldtstraße 4 Braunschweig
Germany Investigational Site - Küchenstraße 10 Braunschweig
Germany Investigational Site - Ritterbrunnen 7 Braunschweig
Germany Investigational Site - Dr.-Franz-Mertens-Str. 8 Bremerhaven
Germany Investigational Site - Georgstraße 44 Bremerhaven
Germany Investigational Site Bruchköbel
Germany Investigational Site Brühl
Germany Investigational Site Bückeburg
Germany Investigational Site Büdingen
Germany Investigational Site Butzbach
Germany Investigational Site - Großer Plan 11 Celle
Germany Investigational Site - Neumarkt 1d Celle
Germany Investigational Site Cottbus
Germany Investigational Site Dorsten
Germany Investigational Site - Hansastraße 14-16 Dortmund
Germany Investigational Site - Markt 4 Dortmund
Germany Investigational Site - Wittbräucker Str. 2 Dortmund
Germany Investigational Site Düsseldorf
Germany Investigational Site Eilenburg
Germany Investigational Site Eisenberg
Germany Investigational Site Erftstadt
Germany Investigational Site - Altessener Str. 400a Essen
Germany Investigational Site - Gerichtsstraße 32 Essen
Germany Investigational Site - Humannstraße 3 Essen
Germany Investigational Site - Rüttenscheider Stern 5 Essen
Germany Investigational Site - Ginnheimer Landstraße 88 Frankfurt /Main
Germany Investigational Site - Bologarostraße 131 Frankfurt a.M.
Germany Investigational Site - Eschersheimer Landstr. 544 Frankfurt a.M.
Germany Investigational Site - Oeder Weg 72 Frankfurt a.M.
Germany Investigational Site Gardelegen
Germany Investigational Site - Zum Ehrenmal 21 Gelsenkirchen
Germany Investigational Site Gera
Germany Investigational Site Gifhorn
Germany Investigational Site Gotha
Germany Investigational Site Grimma
Germany Investigational Site - Diesterwegstraße 39 Halle
Germany Investigational Site - Nimeyerstraße 23 Halle
Germany Investigational Site - Grindelberg 3 Hamburg
Germany Investigational Site - Möllner Landstraße 27 Hamburg
Germany Investigational Site Hannover
Germany Investigational Site Hemmoor
Germany Investigational Site Hochheim
Germany Investigational Site Homburg
Germany Investigational Site Hönow
Germany Investigational Site - Dornburger Straße 17a Jena
Germany Investigational Site - Ernst-Abbe-Platz 3-4 Jena
Germany Investigational Site - Zitzmannstraße 2 Jena
Germany Investigational Site Kaiserslautern
Germany Investigational Site Kamp-Lintfort
Germany Investigational Site Karlsruhe
Germany Investigational Site Kiel
Germany Investigational Site Kleinmanchow
Germany Investigational Site - Hohenstaufenring 59 Köln
Germany Investigational Site - Wilhelm-Ewald-Weg 1 Köln
Germany Investigational Site - Zeppelinstraße 1 Köln
Germany Investigational Site Köln-Zollstock
Germany Investigational Site Königs Wusterhausen
Germany Investigational Site Königswinter
Germany Investigational Site Lahr
Germany Investigational Site Landau/Isar
Germany Investigational Site Landshut
Germany Investigational Site Langenau
Germany Investigational Site Lauterbach
Germany Investigational Site Leipzig
Germany Investigational Site Lindau
Germany Investigational Site Lutherstadt Eisleben
Germany Investigational Site Magdeburg
Germany Investigational Site Marburg
Germany Investigational Site Markkleeberg
Germany Investigational Site Meschede
Germany Investigational Site Nettetal
Germany Investigational Site Neunkirchen
Germany Investigational Site Nienburg
Germany Investigational Site Norderstedt
Germany Investigational Site - August-Bebel-Platz 33-34 Nordhausen
Germany Investigational Site - Bahnhofstraße 17 Nordhausen
Germany Investigational Site - Bahnhofstraße 8 Nordhausen
Germany Investigational Site Offenbach am Main
Germany Investigational Site Offenburg
Germany Investigational Site Oldenburg
Germany Investigational Site Porta Westfalica
Germany Investigational Site - Allee nach Sanssouci 7 Potsdam
Germany Investigational Site - Großbeerenstraße 301 Potsdam
Germany Investigational Site Quakenbrück
Germany Investigational Site Quedlinburg
Germany Investigational Site Recklinghausen
Germany Investigational Site - Materialhofstraße 9-11 Rendsburg
Germany Investigational Site Ribnitz-Damgarten
Germany Investigational Site Rinteln
Germany Investigational Site Rostock
Germany Investigational Site - Berliner Promenade 15 Saarbrücken
Germany Investigational Site - Kaiserslauterer Str. 26 Saarbrücken
Germany Investigational Site - Heckenstraße 10 Salzgitter
Germany Investigational Site - In den Blumentriften 62 Salzgitter
Germany Investigational Site Salzmünde
Germany Investigational Site Schleswig
Germany Investigational Site - Am Ostentor 5 Schwerte
Germany Investigational Site - Karl-Gerharts-Straße 2 Schwerte
Germany Investigational Site Seehausen
Germany Investigational Site Solingen
Germany Investigational Site Sömmerda
Germany Investigational Site Taucha
Germany Investigational Site Teltow
Germany Investigational Site Tostedt
Germany Investigational Site - Fleischstraße 20 Trier
Germany Investigational Site - Kutzbachstraße 7 Trier
Germany Investigational Site - Einsteinstraße 59 Ulm
Germany Investigational Site - Olgastraße 103 Ulm
Germany Investigational Site - Olgastraße 139 Ulm
Germany Investigational Site Velbert
Germany Investigational Site Wesel
Germany Investigational Site Wilhelmshaven
Germany Investigational Site Witten
Germany Investigational Site - Langerfelder Straße 115 Wuppertal
Germany Investigational Site - Morianstraße 10 Wuppertal

Sponsors (1)

Lead Sponsor Collaborator
Ferring Pharmaceuticals

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Overall Mean Change From Baseline in Mean Number of Nighttime Voids at Week 12 The number of nighttime voids was calculated over 48-hours period prior to baseline and week 12 visits. Calculated as Week 12 measure - Baseline measure. Baseline, Week 12 No
Secondary Mean Change From Baseline in Ratio of Nighttime Urine Volume to 24-hour Urine Volume at Week 12 The ratio of nighttime urine volume to 24-hour urine volume is calculated as the urine volume (volume of all voids after going to bed plus the first morning void) / 24-hour urine volume. Ratios are calculated at baseline and week 12 and difference between the two time points is reported here. Baseline, Week 12 No
Secondary Mean Change From Baseline in Initial Period of Undisturbed Sleep at Week 12 Initial period of undisturbed sleep is calculated as the number of hours between falling asleep and waking for the first time during the night to void. Change is calculated at Week 12 - baseline. Baseline, Week 12 No
Secondary Mean Change From Baseline of Total International Prostate Symptom Score (IPSS) at Week 12 The International Prostate Symptoms Score (IPSS) is a self-administered 8 item questionnaire designed to assess urination frequency and Quality of Life (QOL). The first 7 items are summed into a total score and question urination frequency. They are scaled 0-5, with higher numbers indicating greater severity of symptoms. The last question (item 8) concerns QOL and is scaled 0-6 where higher numbers indicate lower quality of life due to symptoms. The total scale across all questions is 0-41, with higher scores representing worse symptoms. Baseline, Week 12 No
Secondary Mean Change From Baseline International Prostate Symptom Score (IPSS) Quality of Life Score at Week 12 The International Prostate Symptoms Score (IPSS) is a self-administered 8 item questionnaire designed to assess urination frequency and Quality of Life (QOL). The last question (item 8) concerns Quality of Life (QOL) and is scaled 0-6 where higher numbers indicate lower quality of life due to symptoms. Higher scores represent worse Quality of Life (QoL). Baseline, Week 12 No
Secondary Mean Change From Baseline in Total Score in Leeds Sleep Evaluation Questionnaire (LSEQ) at Week 12 The LSEQ is a self-administered 10-item visual analog scale questionnaire designed to assess sleep quality. The 10 individual items are scored 1 to 100, with the total score ranging from 0 - 1,000. Higher numbers indicate lower sleep quality. Baseline, Week 12 No
Secondary Change From Baseline in Degree of Bother Due to Frequency of Daytime Voiding Assessed by The International Consultation on Incontinence Modular Questionnaire - Nocturia (ICIQ-N) The ICIQ-N is a self-administered 4-item questionnaire designed to assess the frequency and bother of daytime and nighttime urination. In questions 1 and 2 participants were asked to estimate the frequency of both daytime voiding (all voids before going to bed excluding the first morning void) and rate the degree of bother of daytime urination on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate lower Quality of Life (QoL). Baseline, Week 12 No
Secondary Change From Baseline in Degree of Bother Due to Frequency of Nighttime Voiding Assessed by The International Consultation on Incontinence Modular Questionnaire - Nocturia (ICIQ-N)at Week 12 The ICIQ-N is a self-administered 4-item questionnaire designed to assess the frequency and bother of daytime and nighttime urination. In questions 3 and 4, participants were asked to estimate the frequency of nighttime voiding (number of voids after going to bed plus the first morning void) and rate the degree of bother of nighttime urination on a scale ranging from 0 (not at all) to 10 (a great deal). Higher numbers indicate lower Quality of Life (QOL). Baseline, Week 12 No
Secondary Participants With Treatment Emergent Adverse Events (AEs) Week 1 to Week 12 Yes